# Application of Life Stage Specific Data in the Risk Assessment for Children: Case Study Presentation Using Pesticides

Susan Makris<sup>1</sup>, Kacee Deener<sup>3</sup>, Vicki Dellarco<sup>5</sup>, Elizabeth Doyle<sup>6</sup>, Elaine Cohen-Hubal<sup>4</sup>, Author(s): Ginger Moser<sup>2</sup>, Stephanie Padilla<sup>2</sup>, Tammy Stoker<sup>2</sup>

Affiliation(s): US EPA, <sup>1</sup>Office of Research and Development (ORD), National Center for Environmental

Assessment (NCEA); <sup>2</sup>ORD, National Health and Environmental Effects Research Laboratory (NHEERL); <sup>3</sup>ORD, National Center for Environmental Research (NCER); <sup>4</sup>ORD, National Center for Computational Toxicology (NCCT); <sup>5</sup>Office of Pesticide Programs (OPP); <sup>6</sup>Office of Water (OW)

ChEI Data

# **Atrazine and Chlorpyrifos**

- Widely-used pesticides with documented potential for exposure to children.
- Were undergoing program office risk assessments.

Registrant-Generated

Toxicology and


Exposure Data

- ORD input was essential to the interpretation of life-stage specific susceptibility and was critical to the assessment of risk to children's health.
- Extensive collaboration and consultation between ORD and the Program Offices occurred during the process of developing the risk assessments.

## **Background**

ORD has historically contributed to the risk assessments of specific individual pesticides or classes of pesticides through:

- Test methods development
- Generation of data
- Consultation with the Program Offices.



# **ORD Research**

Research conducted or supported by ORD contributed to characterization of life-stage specific susceptibility issues for each of these two chemicals.

- Atrazine: Identified the critical non-cancer mode of action (MoA) for risk assessment, i.e., disruption to the hypothalamic-pituitary-gonadal axis during development.
- Chlorpyrifos: Characterized age-related sensitivity of behavioral endpoints and cholinesterase inhibition, and the assessment of children's exposure to chlorpyrifos was developed and/or refined.

## **ATRAZINE**

Specific Guidance

# **Risk Assessment Guidelines**

Developmental Tox, revised, 1994 Reproduction, 1996 Neurotoxicity, 1998 Carcinogenicity (draft), 1999

## **Guidance Documents**

FQPA/10X Task Force, 1999 Review of the RfD and RfC Processes, 2002 Child-Specific Exposure Factor Handbook, 2002 Children's Health Risk Assess. Framework, in progress

## **OPPTS Test Guidelines**

Developmental Tox, revised, 1998 Reproduction/Fertility, revised, 1998 Developmental Neurotox, revised, 1998 Developmental Immunotox, in progress,


#### Life-Stage Specific Methods Development Biomarker assays

cross-Agency risk assessment practices.

ORD development of risk assessment (RA) guidelines and guidance has advanced the state of the knowledge in specific scientific areas, e.g., susceptibility, and has provided a strong link between ORD research and chemical risk assessment. This has resulted in higher quality, defensible decisionmaking by the Program Offices and greater consistency in

Endocrine assays

## **CHLORPYRIFOS**



NHEERL Studies

Age-related sensitivity was characterized for the established MoA (cholinesterase inhibition - ChEI)

## Chlorpyrifos – Reregistration Eligibility Decision (2000)

Exposure Scenario	Dose (NOAEL)	Endpoint	Study
Acute Dietary	0.5 m/k/d	Plasma and RBC ChEI	Blood time course study
Chronic Dietary	0.03 m/k/d	Plasma and RBC ChEI	WOE: 2-yr dog; 90-d dog; 2-yr rat; 90-d rat; DNT
Short-term Dermal	0.15 m/k/d	Plasma and RBC ChEI	21-d dermal rat
Intermediate/Long Term Dermal	0.03 m/k/d	Plasma and RBC ChEI	WOE: 2-yr dog; 90-d dog;

Based upon information on sensitivity and susceptibility of the young, and on residual uncertainties regarding potential adverse effects following exposure of children to chlorpyrifos, the 10X FQPA Safety Factor was applied to all children's health risk assessments for chlorpyrifos.

A number of residential uses of chlorpyrifos were cancelled or limited; public awareness of potential risks to susceptible populations was raised; preliminary data suggest positive outcomes on these populations (Whyatt et al. 2004)

# Outcome and Impact

**NHEERL Studies** 

Suppressed

Estrogen-induced

surges of LH and

orolactin, Coope

et al., 1996

Suppressed

prolactin;

developmental

prostatitis: Stoker

et al., 1999

Puberty

Delayed

puberty: Laws

et al., 2000,

Developmental rat

and rabbit

6-mo LH surge

Pubertal assay

6-mo LH surge

(Stoker et al., 2000)

Disrupted

control of

pituitary-ovarian

function, Cooper/

Critical non-cancer MoA for risk assessment identified: disruption to

the hypothalamic-pituitary-gonadal axis during development

Atrazine – Interim Reregistration Eligibility Decision (2003)

Delayed ossification (NOAEL

offspring, Stoker et al., 1999)

for hypothalamic disruption

Delayed preputial separation

for hypothalamic disruption

Public perception of potential risk was refocused away from cancer

and onto neuroendocrine-mediated reproductive/developmental

risks from atrazine exposure to susceptible populations

supported by prostatitis in male

Attenuated LH surge as biomarker

Attenuated LH surge as biomarker

Exposure Scenario Dose (NOAEL) Endpoint

Acute Dietary

Females 13-50

Chronic Dietary

Dermal/Inhalation

Intermediate-Term

Dermal/Inhalation

Short-term

10 m/k/d

1.8 m/k/d

6.25 m/k/d

1.8 m/k/d

puberty:

Stoker et al.

2000, 2002

hypothalamic

Risk management decisions made by the Program Offices addressed the protection of susceptible populations. **Chlorpyrifos:** Residential uses were cancelled in mitigation efforts that became effective in 2001. Earlier CDC biomonitoring studies suggest that levels of urinary metabolites that are indicative of chlorpyrifos exposure are lower in the 1999-2000 period compared to the 1988-1994 period. Additionally, in an NCER-supported study of an urban minority cohort of newborn babies and their mothers (Whyatt et al., 2004), levels of chlorpyrifos in personal air and blood samples were substantially decreased from 1998-2002, and correlations between chlorpyrifos exposure levels and decreased birth weight/length observed in 1998 were no longer apparent in 2002.

Atrazine: Risk communication efforts were critical in refocusing public perception of potential risks, away from longterm cancer concerns (the focus of past risk assessments) and towards non-cancer risks to susceptible populations.

## **ORD** Contribution to Program Office Risk Assessments

- For the atrazine and chlorpyrifos risk assessments, ORD research provided:
- Confirmation of susceptibility in the young
- Support for decisions regarding the adverse consequences of the observed effects
- A basis for extrapolation from animal data to potential human response
- Methodologies to assess exposure to children
- Information critical in identifying the point of departure for risk assessments conducted by OPP and OW.

## **Atrazine References:**

Cooper, RL et al. (1996) Repro. Toxicol. 10(4):257-264. Stoker, TE et al. (1999) Tox. Sci. 52(1):68-79. Cooper, RL et al. (2000) Tox. Sci. 53:297-307. Stoker, TE et al. (2000) *Tox. Sci.* 58:50-59. Laws, SC et al. (2000) Tox. Sci. 58(2):366-76. Stoker, TE et al. (2002) Tox. Sci. 67(2):198-206. Laws, SC et al. (2003) Tox. Sci. 76(1):190-200. USEPA (2003) Atrazine IRED (http://www.epa.gov/oppsrrd1/reregistration/atrazine)

This poster does not necessarily reflect the views or policies of the U.S. EPA.

## **Chlorpyrifos References:**

Atterberry, TT et al. (1997) Tox. Appl. Pharm. 147(2):411-418. Boone, JS et al. (2001) Env. Health Persp. 109(11):1109-1114. Das, KP and Barone, S (1999) Tox. Appl. Pharm. 160:217-230. Carr, RL et al. (2001) Tox. Sci. 59(2):260-267. Hunter, DL et al. (1999) Tox. Appl. Pharm. 158:16-23. Lassiter, TL et al. (1998) Tox. Appl. Pharm. 152:56-65. Lu, C and Fenske, RA (1999) Env. Health Persp. 107(6):463-467. Moser, VC et al. (1998) Tox. Sci. 46:211-222. Moser, VC and Padilla, S (1998) Tox. Appl. Pharm. 149:107-119. Song, X et al. (1997) Tox. Appl. Pharm. 145:158-174. Whyatt, RM et al. (2004) Env. Health. Persp. 112(10):1125-1132. USEPA (2002) Chlorpyrifos IRED

(http://www.epa.gov/oppsrrd1/REDs/chlorpyrifos\_ired.pdf)

ENVIRONMEN AGENCA TAL PROTE

